Your insurance denied Ozempic, Wegovy, or Mounjaro? The denial is usually about paperwork — not you.
GLP-1 weight-loss drugs are among the most tightly managed prescriptions in the country — plans stack prior authorization, step therapy, BMI and comorbidity criteria, and outright weight-loss exclusions on top of one another. Out of pocket, these medications often run well over $1,000 a month, so a denial can put treatment out of reach overnight. Most denials turn on prior-authorization rules, step therapy, plan exclusions, and clinical documentation.
Upload your denial letter. Lysco identifies the exact reason, maps the step-therapy and exception arguments that fit it, and drafts an appeal with clinical citations. Your first review each month is free.
Free to see exactly what’s wrong. $9 to unlock the full appeal — only if you choose to proceed. No subscription. No credit card to start.
Your appeal has a real deadline — and the clock is already running.
Most commercial and ACA marketplace plans give you at least 180 days from the denial notice to file an internal appeal. Medicare Part D drug appeals are shorter: a redetermination request is due within 60 calendar days of receiving the notice — CMS treats that as 65 calendar days from the date printed on it — and some Medicaid timelines are shorter still. The clock starts from the date on the letter — check yours now.
Check my deadline — free reviewThe numbers
<1%
Of denied ACA Marketplace in-network claims were formally appealed
KFF, 2024 data
~1 in 3
Of internal appeals that WERE filed ended with the denial overturned
KFF, 2024 data
$50
Copay for eligible Part D beneficiaries under the short-term Medicare GLP-1 Bridge, running now through Dec 31, 2027
CMS, 2026
The first two figures come from 2024 ACA Marketplace (HealthCare.gov) in-network claims data across all claim types — not GLP-1 claims specifically — and they describe a population, not a prediction for your case. The third is a CMS program fact, not an appeal statistic. GLP-1 outcomes specifically depend on your plan’s step-therapy rules, BMI/comorbidity criteria, and the clinical documentation your prescriber provides.
Drugs covered
Lysco prepares appeals for every major GLP-1
Ozempic
Type 2 diabetes
Wegovy
Weight management · Appeal guide
Mounjaro
Type 2 diabetes
Zepbound
Weight management · Appeal guide
Rybelsus
Type 2 diabetes (oral)
Saxenda
Weight management
Trulicity
Type 2 diabetes
Victoza
Type 2 diabetes
Other GLP-1s
Any brand or generic
Denial playbook
Why insurers deny GLP-1s — and what works in appeal
Step therapy not completed
Insurers often require you to “fail” cheaper drugs (metformin, phentermine) first. If you’ve documented intolerance, contraindication, or prior failure, that waives the requirement. Upload those records and Lysco builds the argument from them.
BMI or comorbidity threshold not met
BMI ≥30, or ≥27 with at least one weight-related condition, are common FDA-labeled adult indications for chronic weight-management drugs such as Wegovy and Zepbound — not a universal plan coverage standard. Compare the denial with the drug label and your plan’s actual criteria.
Weight-loss use not covered
Many plans exclude weight-management indications but cover Type 2 diabetes. If you have related conditions, we cite ADA and endocrinology guidelines for broader medical necessity.
Prior authorization required
Many GLP-1 denials are PA failures, step-therapy issues, or plan-exclusion questions rather than a pure medical rejection. Lysco prepares the prior-authorization appeal draft and a documentation checklist your prescriber can use to resubmit — you or your prescriber submit it.
Plan formulary exclusion
If the specific drug isn’t on formulary but a similar GLP-1 is, Lysco drafts a formulary-exception request with clinical justification for why your prescriber chose this one — you or your prescriber submit it to the plan.
Quantity or dose limits
If your prescriber escalated your dose per the approved titration schedule, the denial is often procedurally wrong. We cite the FDA-approved titration.
What changed
Why 2026 is different
Medicare is testing a limited bridge. The Medicare GLP-1 Bridge is a short-term CMS demonstration that began July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D beneficiaries pay a $50 copay for certain GLP-1 drugs. You have to be 18 or older and meet a BMI threshold (35 or higher, or lower with specific conditions), your provider has to complete a prior authorization and confirm you are also following a diet-and-exercise program, and you are not eligible if your own Part D plan already covers your GLP-1. The demonstration sits outside the Part D benefit’s normal coverage and payment flow — the deductible does not apply, the copay does not count toward your out-of-pocket total, and it is not blanket Medicare coverage. Check the current rules at medicare.gov/glp1bridge.
State Medicaid is contracting. Effective January 1, 2026, Pennsylvania, California, New Hampshire, and South Carolina ended Medicaid coverage of GLP-1s for obesity. KFF counts 13 state Medicaid programs still covering them for obesity as of January 2026, down from 16 in 2025. If you’re on Medicaid and lost coverage, an appeal — or a shift to a covered indication — may still work.
Commercial plans are tightening. From 2025 to 2026, roughly 12 million people were on plans that dropped Wegovy coverage, and about 12 million were on plans that dropped Zepbound, as KFF Health News reported in June 2026. Plans that still cover GLP-1 weight-loss drugs commonly require prior authorization, so documentation is what the appeal turns on. Lysco builds that documentation into every appeal draft.
Formulary swaps are triggering denials of their own. In 2025 CVS Caremark removed Zepbound from its main commercial formulary and made Wegovy the preferred obesity GLP-1 — and in May 2026 announced that Zepbound returns to that formulary as a co-preferred option from October 1, 2026. If a formulary change like this forced you off a drug that was working, a formulary-exception request with clinical justification is often the right appeal path. See the CVS Caremark / Zepbound guide.
The process
How Lysco prepares a GLP-1 appeal
Upload the denial or PA rejection
A picture, a PDF, or the text pasted in. Lysco extracts the specific reason for the denial.
We identify the fix
Step therapy? BMI threshold? Formulary exclusion? We match the denial to the right appeal argument.
We draft the appeal with clinical citations
ADA guidelines, endocrinology society statements, FDA-approved titration schedules, and your plan’s own policy language.
You review, sign, and send
Or give it to your prescriber to co-sign. We include the exact submission address and deadline.
Your exact situation
Go deeper on your specific denial
Wegovy denied
The cardiovascular-indication path, semaglutide step therapy, and the Ozempic same-molecule question.
Zepbound denied
The sleep-apnea indication, tirzepatide titration limits, and the Mounjaro formulary-exception argument.
Step therapy / fail-first
The five recognized exception grounds, state override laws, and what counts as a documented failure.
Weight loss not covered
Plan-design exclusions vs medical-necessity denials — and the covered-indication pivot that can beat both.
CVS Caremark dropped Zepbound
The 2025 formulary switch, the October 2026 reversal, and the exception path in between.
Questions
GLP-1 appeal questions, answered straight
How much does it cost?
Is my denial letter private?
My denial says weight-loss drugs aren’t covered. Is an appeal still possible?
How long do I have to appeal?
Do I need my doctor to appeal?
Does Lysco submit the appeal for me?
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications. GLP-1 prescribing is a decision for you and your doctor. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Ozempic, Wegovy, Mounjaro, and Zepbound are trademarks of their respective manufacturers.